Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
26
08
2018
accepted:
15
01
2019
pubmed:
19
1
2019
medline:
3
6
2020
entrez:
19
1
2019
Statut:
ppublish
Résumé
Systemic light chain amyloidosis is a rare and life-threatening disorder, for which accurate risk stratification is crucial. Current cardiac staging systems (MAYO2004, MAYO3b, and MAYO2012) are mainly based on biomarkers, which have uncertain reliability in the context of atrial fibrillation, arrhythmia or pacemaker stimulation as well as renal insufficiency. We compared the performance of the established staging systems with particular regard to these comorbidities in 1,224 patients with systemic light chain amyloidosis diagnosed at our center from July 2002 until March 2017. We first characterized the subsets with an estimated glomerular filtration rate <50 mL/min/1.73 m
Identifiants
pubmed: 30655373
pii: haematol.2018.205336
doi: 10.3324/haematol.2018.205336
pmc: PMC6601086
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1451-1459Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Biom J. 2006 Dec;48(6):1029-40
pubmed: 17240660
J Clin Oncol. 2004 Sep 15;22(18):3751-7
pubmed: 15365071
Blood. 2017 Aug 3;130(5):632-642
pubmed: 28550043
Blood. 2017 Aug 3;130(5):625-631
pubmed: 28546143
Circ Heart Fail. 2017 Oct;10(10):
pubmed: 29018174
Leukemia. 2012 Nov;26(11):2317-25
pubmed: 22475872
Blood. 2014 Oct 9;124(15):2325-32
pubmed: 25115890
Circulation. 2003 May 20;107(19):2440-5
pubmed: 12719281
Hepatology. 1997 Jan;25(1):118-21
pubmed: 8985276
Am J Clin Pathol. 2003 Feb;119(2):274-8
pubmed: 12579999
Blood. 2010 Oct 7;116(14):2455-61
pubmed: 20581312
Blood. 2010 Nov 4;116(18):3426-30
pubmed: 20644111
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Am J Cardiol. 2017 Dec 1;120(11):2061-2064
pubmed: 29033047
Leukemia. 2016 Oct;30(10):1979-1986
pubmed: 27416985
Eur J Heart Fail. 2008 Sep;10(9):824-39
pubmed: 18760965
Br J Haematol. 2016 Jan;172(2):170-86
pubmed: 26491974
J Cardiol. 2018 Apr;71(4):419-427
pubmed: 29153741
Br J Haematol. 2018 Nov;183(3):506-509
pubmed: 29082513
Cancer Med. 2016 Jul;5(7):1464-72
pubmed: 27109862
Amyloid. 2017 Mar;24(1):52-59
pubmed: 28434267
Eur Heart J. 2006 Feb;27(4):447-53
pubmed: 16299020
Clin Chem. 2017 Jan;63(1):59-65
pubmed: 27811207
Heart. 2014 Mar;100(5):383-8
pubmed: 24402772
Lancet. 2003 May 24;361(9371):1787-9
pubmed: 12781539
Congest Heart Fail. 2010 Sep-Oct;16(5):214-20
pubmed: 20887618
Stat Med. 2013 Jun 15;32(13):2173-84
pubmed: 23172755
Mayo Clin Proc. 2008 Mar;83(3):297-303
pubmed: 18315995
Circulation. 2017 Apr 4;135(14):1357-1377
pubmed: 28373528
Blood. 2013 Apr 25;121(17):3420-7
pubmed: 23479568
Clin Biochem. 2017 Oct;50(15):813-815
pubmed: 28392226
Am J Hematol. 2015 Jun;90(6):524-8
pubmed: 25753178
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953